{
    "id": 30653,
    "fullName": "RYR1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RYR1 mutant indicates an unspecified mutation in the RYR1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 6261,
        "geneSymbol": "RYR1",
        "terms": [
            "RYR1",
            "CCO",
            "MHS",
            "MHS1",
            "PPP1R137",
            "RYDR",
            "RYR",
            "RYR-1",
            "SKRR"
        ]
    },
    "variant": "mutant",
    "createDate": "08/02/2019",
    "updateDate": "08/02/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17936,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, RYR1 mutations were associated with improved response to treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Yervoy (ipilimumab), and Keytruda (pembrolizumab) in non-small cell lung cancer patients, as indicated by enrichment in the durable clinical benefit group (12/51, 24% vs 2/55, 4%, p<0.001) compared to the no durable benefit group (PMID: 31290993).",
            "molecularProfile": {
                "id": 32883,
                "profileName": "RYR1 mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15883,
                    "pubMedId": 31290993,
                    "title": "Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31290993"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17935,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, RYR1 mutations were associated with improved response to treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Yervoy (ipilimumab), and Keytruda (pembrolizumab) in non-small cell lung cancer patients, as indicated by enrichment in the durable clinical benefit group (12/51, 24% vs 2/55, 4%, p<0.001) compared to the no durable benefit group (PMID: 31290993).",
            "molecularProfile": {
                "id": 32883,
                "profileName": "RYR1 mutant"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15883,
                    "pubMedId": 31290993,
                    "title": "Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31290993"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17934,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, RYR1 mutations were associated with improved response to treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Yervoy (ipilimumab), and Keytruda (pembrolizumab) in non-small cell lung cancer patients, as indicated by enrichment in the durable clinical benefit group (12/51, 24% vs 2/55, 4%, p<0.001) compared to the no durable benefit group (PMID: 31290993).",
            "molecularProfile": {
                "id": 32883,
                "profileName": "RYR1 mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15883,
                    "pubMedId": 31290993,
                    "title": "Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31290993"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32883,
            "profileName": "RYR1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}